![]() |
|||||||
|
Fusion Protein:RHPN2-GRIN2D |
Fusion Gene and Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: RHPN2-GRIN2D | FusionPDB ID: 74026 | FusionGDB2.0 ID: 74026 | Hgene | Tgene | Gene symbol | RHPN2 | GRIN2D | Gene ID | 85415 | 2906 |
Gene name | rhophilin Rho GTPase binding protein 2 | glutamate ionotropic receptor NMDA type subunit 2D | |
Synonyms | P76RBE|RHOBP | EB11|EIEE46|GluN2D|NMDAR2D|NR2D | |
Cytomap | 19q13.11 | 19q13.33 | |
Type of gene | protein-coding | protein-coding | |
Description | rhophilin-276 kDa RhoB effector proteinGTP-Rho-binding protein 2rhophilin-like Rho-GTPase binding protein | glutamate receptor ionotropic, NMDA 2DN-methyl D-aspartate receptor subtype 2DN-methyl-d-aspartate receptor subunit 2Destrogen receptor binding CpG islandglutamate [NMDA] receptor subunit epsilon-4glutamate receptor, ionotropic, N-methyl D-aspartate | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | . | O15399 Main function of 5'-partner protein: FUNCTION: Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+) (PubMed:9489750, PubMed:27616483, PubMed:26875626, PubMed:28126851). Sensitivity to glutamate and channel kinetics depend on the subunit composition (PubMed:9489750). {ECO:0000269|PubMed:26875626, ECO:0000269|PubMed:27616483, ECO:0000269|PubMed:28095420, ECO:0000269|PubMed:28126851, ECO:0000269|PubMed:9489750}. | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000588683, ENST00000400226, ENST00000254260, | ENST00000263269, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 18 X 12 X 11=2376 | 5 X 9 X 5=225 |
# samples | 29 | 8 | |
** MAII score | log2(29/2376*10)=-3.03441003078583 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(8/225*10)=-1.49185309632967 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Fusion gene context | PubMed: RHPN2 [Title/Abstract] AND GRIN2D [Title/Abstract] AND fusion [Title/Abstract] | ||
Fusion neoantigen context | PubMed: RHPN2 [Title/Abstract] AND GRIN2D [Title/Abstract] AND neoantigen [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | RHPN2(33481420)-GRIN2D(48919259), # samples:3 | ||
Anticipated loss of major functional domain due to fusion event. | RHPN2-GRIN2D seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. RHPN2-GRIN2D seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. RHPN2-GRIN2D seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. RHPN2-GRIN2D seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. RHPN2-GRIN2D seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. RHPN2-GRIN2D seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | GRIN2D | GO:0097553 | calcium ion transmembrane import into cytosol | 26875626 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:33481420/chr19:48919259) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
Top |
Fusion Amino Acid Sequences |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000254260 | RHPN2 | chr19 | 33481420 | - | ENST00000263269 | GRIN2D | chr19 | 48919259 | + | 5260 | 1836 | 36 | 4265 | 1409 |
ENST00000254260 | RHPN2 | chr19 | 33481419 | - | ENST00000263269 | GRIN2D | chr19 | 48919258 | + | 5260 | 1836 | 36 | 4265 | 1409 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000254260 | ENST00000263269 | RHPN2 | chr19 | 33481420 | - | GRIN2D | chr19 | 48919259 | + | 0.002680955 | 0.99731904 |
ENST00000254260 | ENST00000263269 | RHPN2 | chr19 | 33481419 | - | GRIN2D | chr19 | 48919258 | + | 0.002680955 | 0.99731904 |
![]() |
Get the fusion protein sequences from here. |
Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for RHPN2-GRIN2D |
![]() |
Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
RHPN2 | chr19 | 33481419 | GRIN2D | chr19 | 48919258 | 1836 | 600 | MKVVSLLDSTSSMVFYQRADMAIGSL |
RHPN2 | chr19 | 33481419 | GRIN2D | chr19 | 48919258 | 1836 | 984 | AEAAPPPAKPPPPPQPLPSPAYPAPR |
RHPN2 | chr19 | 33481420 | GRIN2D | chr19 | 48919259 | 1836 | 600 | MKVVSLLDSTSSMVFYQRADMAIGSL |
RHPN2 | chr19 | 33481420 | GRIN2D | chr19 | 48919259 | 1836 | 984 | AEAAPPPAKPPPPPQPLPSPAYPAPR |
Top |
Potential FusionNeoAntigen Information of RHPN2-GRIN2D in HLA I |
![]() |
![]() * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
Top |
Potential FusionNeoAntigen Information of RHPN2-GRIN2D in HLA II |
![]() |
![]() * We used NetMHCIIpan v4.1 (%rank<0.5). |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
Top |
Fusion breakpoint peptide structures of RHPN2-GRIN2D |
![]() * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of RHPN2-GRIN2D |
![]() * We used Glide to predict the interaction between HLAs and neoantigens. |
HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
Top |
Vaccine Design for the FusionNeoAntigens of RHPN2-GRIN2D |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
Top |
Information of the samples that have these potential fusion neoantigens of RHPN2-GRIN2D |
![]() |
Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
Top |
Potential target of CAR-T therapy development for RHPN2-GRIN2D |
![]() |
![]() * Minus value of BPloci means that the break point is located before the CDS. |
- In-frame and retained 'Transmembrane'. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Tgene | GRIN2D | chr19:33481419 | chr19:48919258 | ENST00000263269 | 5 | 13 | 585_603 | 0 | 1337.0 | Transmembrane | Helical | |
Tgene | GRIN2D | chr19:33481419 | chr19:48919258 | ENST00000263269 | 5 | 13 | 658_673 | 0 | 1337.0 | Transmembrane | Helical | |
Tgene | GRIN2D | chr19:33481419 | chr19:48919258 | ENST00000263269 | 5 | 13 | 845_864 | 0 | 1337.0 | Transmembrane | Helical | |
Tgene | GRIN2D | chr19:33481420 | chr19:48919259 | ENST00000263269 | 5 | 13 | 585_603 | 0 | 1337.0 | Transmembrane | Helical | |
Tgene | GRIN2D | chr19:33481420 | chr19:48919259 | ENST00000263269 | 5 | 13 | 658_673 | 0 | 1337.0 | Transmembrane | Helical | |
Tgene | GRIN2D | chr19:33481420 | chr19:48919259 | ENST00000263269 | 5 | 13 | 845_864 | 0 | 1337.0 | Transmembrane | Helical |
![]() * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
RHPN2 | chr19 | 33481419 | ENST00000254260 | GRIN2D | chr19 | 48919258 | ENST00000263269 | ![]() |
Top |
Related Drugs to RHPN2-GRIN2D |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to RHPN2-GRIN2D |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |